Drugs / iEPCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05993884 | Aug 2023 → Apr 2025 | ischemic stroke | Allife Medical Science and Technology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iEPCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05993884 ↗ |
| Action | Restore | “They can effectively repair endothelial cells with vascular injuries” NCT05993884 ↗ |
| Modality | Cell therapy | “Endothelial progenitor cells (EPCs) have the potential to reduce brain damage from AIS.” NCT05993884 ↗ |
| Route | Intravenous | “Patients receive iEPCs IV with the single dose” NCT05993884 ↗ |